CRTX Cortexyme, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

CRTX [NASD]

Cortexyme, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	1.10%	Shs Outstand	28.26M	Perf Week	7.48%
Market Cap	1.26B	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-42.24%	Shs Float	15.58M	Perf Month	-0.11%
Income	-48.50M	PEG	-	EPS next Q	-0.62	Inst Own	39.30%	Short Float	9.95%	Perf Quarter	-1.66%
Sales	-	P/S	-	EPS this Y	-305.10%	Inst Trans	2.40%	Short Ratio	10.57	Perf Half Y	-29.61%
Book/sh	7.72	P/B	5.84	EPS next Y	-3.40%	ROA	-30.70%	Target Price	-	Perf Year	51.97%
Cash/sh	5.80	P/C	7.77	EPS next 5Y	18.30%	ROE	-32.50%	52W Range	19.35 - 73.84	Perf YTD	-19.63%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-38.89%	Beta	-
Dividend %	-	Quick Ratio	12.90	Sales past 5Y	-	Gross Margin	-	52W Low	133.18%	ATR	2.13
Employees	23	Current Ratio	12.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	54.42	Volatility	4.92% 4.45%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-178.30%	Profit Margin	-	Rel Volume	0.43	Prev Close	44.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	146.55K	Price	45.12
Recom	2.10	SMA20	5.76%	SMA50	0.32%	SMA200	3.13%	Volume	64,016	Change	2.55%

Jun-24-20

Initiated

H.C. Wainwright

Buy

$76

Jun-02-20

Initiated

Jefferies

Buy

$59

Jun-03-19

Initiated

JMP Securities

Mkt Outperform

$53

Jun-03-19

Initiated

Credit Suisse

Underperform

$14

Jun-03-19

Initiated

Canaccord Genuity

Buy

$42

Jun-03-19

Initiated

BofA/Merrill

Neutral

$28

Aug-12-20 08:11AM	We're Hopeful That Cortexyme (NASDAQ:CRTX) Will Use Its Cash Wisely Simply Wall St.
08:10AM	Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation Simply Wall St.
Aug-06-20 04:05PM	Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020 Business Wire
Jul-29-20 08:00AM	Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020 Business Wire
Jul-28-20 06:09PM	Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases Business Wire
Jul-22-20 08:00AM	Cortexyme Announces Upcoming Data Presentations at the Alzheimers Association International Conference 2020 Business Wire
Jun-14-20 07:00AM	4 Biotech Stocks That Are Seeing Big Buys in June Barrons.com
Jun-12-20 04:27PM	Hedge Funds Are Buying Cortexyme, Inc. (CRTX) Insider Monkey
Jun-09-20 08:00AM	Cortexyme Announces "Atuzaginstat" Selected as First-in-Class Nonproprietary Name for COR388 Business Wire +11.12%
Jun-02-20 09:44AM	Benzinga's Top Upgrades, Downgrades For June 2, 2020 Benzinga
May-27-20 08:00AM	Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020 Business Wire
May-14-20 11:44AM	Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock? Simply Wall St.
May-12-20 04:05PM	Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update Business Wire
May-07-20 08:00AM	Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020 Business Wire
May-06-20 08:30AM	Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimers-Like Pathology in the Journal of Alzheimers Disease Business Wire
Apr-30-20 04:05PM	Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary Business Wire
Apr-06-20 08:30AM	Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020 Business Wire +11.08%
Apr-02-20 08:00AM	Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimers Pathology at Advances in Alzheimers and Parkinsons Therapies Virtual Focus Meeting 2020 Business Wire -14.42%
Mar-17-20 08:00AM	Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Business Wire +17.27%
Mar-16-20 08:00AM	Cortexyme Announces Gain Trial in Alzheimers Disease Has Reached Enrollment Milestone of 300 Patients Business Wire -8.89%
Feb-13-20 08:00AM	Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimers Disease Business Wire
Feb-10-20 04:05PM	Cortexyme Announces Closing of $125 Million Private Placement Business Wire
Feb-05-20 09:00PM	Cortexyme Announces $125 Million Private Placement Business Wire
Jan-30-20 08:18AM	Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Companys Lead Investigational Medicine Business Wire
Jan-13-20 08:00AM	Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimers Disease Business Wire
Jan-08-20 04:05PM	Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020 Business Wire
Jan-05-20 08:14AM	Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation Simply Wall St.
Jan-03-20 10:15AM	Last year's Bay Area IPO performances show why it pays to be an insider American City Business Journals -8.92%
Dec-22-19 06:38PM	Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX) Insider Monkey
Dec-13-19 11:16AM	The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber Zacks +11.00%
Dec-11-19 06:32PM	5 Hottest IPOs of 2019 Zacks
Dec-09-19 08:44AM	Fiverr Languishes Below IPO Price as First Chance to Sell Nears Bloomberg +12.72%
Dec-07-19 01:00PM	Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimers Disease Business Wire
Dec-02-19 01:56PM	Biogen's shares drop on critical view of Alzheimer's data MarketWatch +8.00%
Nov-26-19 04:05PM	Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019 Business Wire
Nov-12-19 04:05PM	Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-08-19 10:34AM	The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme Zacks +5.25%
Nov-07-19 08:18AM	4 Best-Performing IPOs So Far in 2019 Zacks +7.99%
Nov-01-19 08:00AM	Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimers Disease 2019 Business Wire
Oct-09-19 09:14AM	Top Ranked Momentum Stocks to Buy for October 9th Zacks
Oct-07-19 09:36AM	Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares? Simply Wall St.
Sep-26-19 08:00AM	Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial Business Wire
Sep-23-19 10:54AM	Top Ranked Momentum Stocks to Buy for September 23rd Zacks
Aug-08-19 11:45AM	What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own? Simply Wall St. -9.63%
Jul-31-19 04:05PM	Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th Business Wire
Jul-17-19 11:00AM	Cortexymes Approach to Addressing a Key Underlying Cause of Alzheimers Detailed at Alzheimers Association International Conference 2019 Business Wire
Jul-10-19 08:00AM	Cortexyme Announces Upcoming Data Presentations at the Alzheimers Association International Conference 2019 Business Wire
Jul-05-19 10:05AM	These Bay Area companies are part of an uptick in women-led IPOs American City Business Journals -6.21%
Jul-01-19 02:08PM	Here are big Bay Area winners, losers from busy first half of IPOs American City Business Journals +6.52%
Jun-26-19 12:31PM	Cortexyme's unique approach to Alzheimer's research Yahoo Finance Video
Jun-19-19 08:00AM	Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts Business Wire
Jun-10-19 08:00AM	Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019 Business Wire
May-08-19 07:22PM	Cortexyme, Inc. Announces Pricing of Initial Public Offering Business Wire
May-04-19 05:25PM	IPO Outlook For The Week: Uber (And 11 Others) Benzinga

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EPIQ Capital Group, LLC	IA/Managing Member of 10% Owne	Jun 12	Buy	44.06	2,440	107,506	2,860,967	Jun 15 06:55 PM
EPIQ Capital Group, LLC	IA/Managing Member of 10% Owne	Jun 11	Buy	44.32	6,600	292,512	2,858,527	Jun 15 06:55 PM
Lamond David	Director	Jun 04	Buy	43.27	49,125	2,125,795	1,747,109	Jun 08 06:47 PM
PFIZER INC	10% Owner	Jun 03	Sale	40.18	370,000	14,866,600	2,879,973	Jun 04 04:25 PM
Detke Michael J.	Chief Medical Officer	May 27	Option Exercise	6.91	5,515	38,109	28,261	May 29 04:48 PM
EPIQ Capital Group, LLC	IA/Managing Member of 10% Owne	May 22	Buy	55.90	2,085	116,552	2,851,927	May 22 06:03 PM
EPIQ Capital Group, LLC	IA/Managing Member of 10% Owne	May 21	Buy	55.80	520	29,016	2,849,842	May 22 06:03 PM
EPIQ Capital Group, LLC	IA/Managing Member of 10% Owne	May 20	Buy	57.95	6,085	352,605	2,849,322	May 22 06:03 PM
Lamond David	Director	May 19	Buy	56.24	39,200	2,204,683	1,697,984	May 19 06:41 PM
Lamond David	Director	May 15	Buy	48.93	5,448	266,569	1,658,784	May 19 06:41 PM
Detke Michael J.	Chief Medical Officer	Apr 02	Option Exercise	6.91	5,515	38,109	22,746	Apr 06 05:39 PM
Detke Michael J.	Chief Medical Officer	Feb 07	Option Exercise	6.91	17,231	119,066	17,231	Feb 10 06:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience